ReviewCurrent allergy and asthma reports2015
Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases.
Review in Current allergy and asthma reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Gut microbiota and ulcerative colitis: a bibliometric analysis of knowledge structure, research hotspots, and future directions.Frontiers in microbiology · 2026Pooled it
- The Intestinal Macrophage-Intestinal Stem Cell Axis in Inflammatory Bowel Diseases: From Pathogenesis to Therapy.International journal of molecular sciences · 2025Review
- Yeast peptides alleviate diarrhea in neonatal lambs by enhancing the colonic barrier function and modulating colonic microbiota.Frontiers in veterinary science · 2025Article
- The Potential of the Probiotic IsolateFood science & nutrition · 2025Article
- Potential of natural products and gut microbiome in tumor immunotherapy.Chinese medicine · 2024Review
- Geohelminths: Use in the Treatment of Selected Human Diseases.Pathogens (Basel, Switzerland) · 2024Review
- ITGB2 related to immune cell infiltration as a potential therapeutic target of inflammatory bowel disease using bioinformatics and functional research.Journal of cellular and molecular medicine · 2024Article
- Potential mechanisms underlying inhibition of xenograft lung cancer models by kaempferol: modulation of gut microbiota in activating immune cell function.Journal of Cancer · 2024Article
- Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies.CHEST pulmonary · 2023Review
- Investigating association between inflammatory bowel disease and rotavirus vaccination in a paediatric cohort in the UK.Epidemiology and infection · 2023Article
- Article
- Acute Gastroenteritis in the Etiology of Inflammatory Bowel Disease: Systematic Review and Meta-analysis.Crohn's & colitis 360 · 2021Article
- Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease.International journal of molecular sciences · 2021Review
- Recipient factors in faecal microbiota transplantation: one stool does not fit all.Nature reviews. Gastroenterology & hepatology · 2021Review
- Role of Vitamin K in Intestinal Health.Frontiers in immunology · 2021Review
- Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases.Frontiers in immunology · 2020Review
- Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases.Journal of gastroenterology · 2020Review
- Bioinformatics Analysis of Gut Microbiota and CNS Transcriptome in Virus-Induced Acute Myelitis and Chronic Inflammatory Demyelination; Potential Association of Distinct Bacteria With CNS IgA Upregulation.Frontiers in immunology · 2020Article
- MushroomFrontiers in nutrition · 2020Article
- Innate Lymphoid Cells in Crohn's Disease.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are characterized by chronic, T-cell-mediated inflammation of the gastrointestinal tract that can cause significant, lifelong morbidity. Data from both human and animal studies indicate that IBDs are likely caused by dysregulated immune responses to resident intestinal microbes. Certain products from mycobacteria, fungi, and Clostridia stimulate increased effector T cell responses during intestinal inflammation, whereas other bacterial products from Clostridia and Bacteroides promote anti-inflammatory regulatory T cell responses. Antibody responses to bacterial and fungal components may help predict the severity of IBDs. While most currently approved treatments for IBDs generally suppress the patient's immune system, our growing understanding of microbial influences in IBDs will likely lead to the development of new diagnostic tools and therapies that target the intestinal microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.